TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELA Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.97−0.00 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $55.71M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
67.7%+6.0 pts over 5 years
Operating margin
-42.0%+96.7 pts over 5 years
Net margin
-48.4%+109.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +15.8% | +24.7% | +34.5% | – | |
| Gross profit | +16.9% | +26.2% | +37.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -72.0% | -223.4% | |
| Return on assets | – | -37.3% | -46.2% | |
| Current ratio | – | 12.60 | 4.20 | |
| Debt to equity | – | – | 8.82 | |
| Interest coverage | – | -7.1× | -6.4× | |
| Inventory turnover | – | 1.6× | 2.2× | |
| Capex to revenue | – | 0.9% | 0.6% | |
| Diluted shares | – | 13M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
TELA Bio generated $181.85M from operations and spent $3.55M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$181.85M
Used
$3.55M
Capital expenditure$3.55M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-48.4%
×Asset turnover0.96×
×Equity multiplier4.83×
=Return on equity, FY2025-223.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -48.4% | 0.96× | 4.83× | -223.4% |
| FY2024 | -54.6% | 0.84× | 3.48× | -159.9% |
| FY2023 | -79.8% | 0.80× | 4.40× | -281.2% |
| FY2022 | -106.9% | 0.64× | 3.79× | -257.5% |
| FY2021 | -112.9% | 0.40× | 2.16× | -96.3% |
| FY2020 | -158.1% | 0.24× | 1.93× | -72.0% |
| FY2019 | -145.2% | 0.32× | -0.89× | 42.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$38.83M
- Cash generatingOperating cash flow above zero-$28.22M
- Return on assets improvedROA up on the prior year-48.5% → -44.9%
- Earnings backed by cashOperating cash flow above net income-$28.22M vs -$38.83M
- Less leverageLong-term debt to assets fell47.5% → 68.4%
- Better liquidityCurrent ratio rose5.01 → 4.20
- No dilutionShare count did not rise29M → 47M
- Gross margin improvedGross margin up on the prior year67.08% → 67.69%
- More efficientAsset turnover rose0.89 → 0.93